- Home
- ROIV vs CIEN Comparison
ROIV vs CIEN Comparison
Compare ROIV & CIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROIV | CIEN |
|---|---|---|
| Founded | 2014 | 1992 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 32.4B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | ROIV | CIEN |
|---|---|---|
| Price | $22.24 | $241.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $24.31 | ★ $219.29 |
| AVG Volume (30 Days) | ★ 8.2M | 3.0M |
| Earning Date | 02-09-2026 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.55 |
| EPS | N/A | ★ 0.85 |
| Revenue | $20,329,000.00 | ★ $4,769,507,000.00 |
| Revenue This Year | N/A | $27.20 |
| Revenue Next Year | $741.42 | $15.92 |
| P/E Ratio | ★ N/A | $284.33 |
| Revenue Growth | N/A | ★ 18.79 |
| 52 Week Low | $8.73 | $49.21 |
| 52 Week High | $23.47 | $248.00 |
Technical Indicators
Market Signals| Indicator | ROIV | CIEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.09 | 66.26 |
| Support Level | $21.60 | $201.70 |
| Resistance Level | $22.72 | $243.00 |
| Average True Range (ATR) | 0.82 | 11.51 |
| MACD | -0.00 | 2.06 |
| Stochastic Oscillator | 61.77 | 86.39 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CIEN Ciena Corporation
Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.